Fra-1 regulates its target genes via binding to remote enhancers without exerting major control on chromatin architecture in triple negative breast cancers.
Binding Sites
Cell Line, Tumor
Chromatin
/ chemistry
Enhancer Elements, Genetic
Epigenesis, Genetic
Fos-Related Antigen-2
/ metabolism
Gene Expression Regulation, Neoplastic
Humans
Nucleotide Motifs
Promoter Regions, Genetic
Proto-Oncogene Proteins c-fos
/ metabolism
Transcription Factor AP-1
/ metabolism
Triple Negative Breast Neoplasms
/ genetics
p300-CBP Transcription Factors
/ metabolism
Journal
Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011
Informations de publication
Date de publication:
18 03 2021
18 03 2021
Historique:
accepted:
25
01
2021
revised:
21
12
2020
received:
13
03
2020
pubmed:
4
2
2021
medline:
27
3
2021
entrez:
3
2
2021
Statut:
ppublish
Résumé
The ubiquitous family of dimeric transcription factors AP-1 is made up of Fos and Jun family proteins. It has long been thought to operate principally at gene promoters and how it controls transcription is still ill-understood. The Fos family protein Fra-1 is overexpressed in triple negative breast cancers (TNBCs) where it contributes to tumor aggressiveness. To address its transcriptional actions in TNBCs, we combined transcriptomics, ChIP-seqs, machine learning and NG Capture-C. Additionally, we studied its Fos family kin Fra-2 also expressed in TNBCs, albeit much less. Consistently with their pleiotropic effects, Fra-1 and Fra-2 up- and downregulate individually, together or redundantly many genes associated with a wide range of biological processes. Target gene regulation is principally due to binding of Fra-1 and Fra-2 at regulatory elements located distantly from cognate promoters where Fra-1 modulates the recruitment of the transcriptional co-regulator p300/CBP and where differences in AP-1 variant motif recognition can underlie preferential Fra-1- or Fra-2 bindings. Our work also shows no major role for Fra-1 in chromatin architecture control at target gene loci, but suggests collaboration between Fra-1-bound and -unbound enhancers within chromatin hubs sometimes including promoters for other Fra-1-regulated genes. Our work impacts our view of AP-1.
Identifiants
pubmed: 33533919
pii: 6127268
doi: 10.1093/nar/gkab053
pmc: PMC7968996
doi:
Substances chimiques
Chromatin
0
FOSL2 protein, human
0
Fos-Related Antigen-2
0
Proto-Oncogene Proteins c-fos
0
Transcription Factor AP-1
0
fos-related antigen 1
0
p300-CBP Transcription Factors
EC 2.3.1.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2488-2508Subventions
Organisme : Medical Research Council
ID : MC_UU_00016/14
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12009/15
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N00969X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106130/Z/14/Z
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.
Références
Oncogene. 2010 Aug 19;29(33):4732-40
pubmed: 20543861
Oncogene. 1997 Feb 20;14(7):837-47
pubmed: 9047391
Elife. 2019 Jul 11;8:
pubmed: 31294690
Nat Rev Cancer. 2010 Jan;10(1):65-76
pubmed: 20029425
Essays Biochem. 2019 Apr 23;63(1):157-165
pubmed: 30940740
Eur J Cancer. 2005 Nov;41(16):2449-61
pubmed: 16199154
Oncogene. 2012 Mar 22;31(12):1493-503
pubmed: 21822309
Nat Genet. 2007 Mar;39(3):311-8
pubmed: 17277777
Mol Cell Biol. 1999 Jan;19(1):330-41
pubmed: 9858557
Bioessays. 2018 Oct;40(10):e1800078
pubmed: 30144132
Mol Cell Biol. 2002 Jan;22(2):587-98
pubmed: 11756554
Nat Methods. 2016 Jan;13(1):74-80
pubmed: 26595209
Breast Cancer Res. 2018 Jan 30;20(1):9
pubmed: 29382358
BMC Cancer. 2007 Jan 25;7:17
pubmed: 17254320
Mol Cell Biol. 2008 Sep;28(18):5764-76
pubmed: 18644873
Genes Cells. 2003 Mar;8(3):263-73
pubmed: 12622723
Genome Res. 2015 Apr;25(4):504-13
pubmed: 25677180
Cell Death Differ. 2015 Feb;22(2):336-50
pubmed: 25301070
Mol Cell Biol. 2003 Jun;23(12):4401-15
pubmed: 12773579
Nature. 2014 Mar 27;507(7493):455-461
pubmed: 24670763
BMC Cancer. 2013 Sep 28;13:441
pubmed: 24073962
J Mol Biol. 1986 Apr 5;188(3):415-31
pubmed: 3525846
Mol Cell Biol. 1991 May;11(5):2451-9
pubmed: 1901942
Mol Cell. 2010 Apr 9;38(1):114-27
pubmed: 20385094
Cell Signal. 2007 Apr;19(4):695-704
pubmed: 17052890
Mol Cell Biol. 2004 Jun;24(11):4696-709
pubmed: 15143165
Nat Genet. 2020 Dec;52(12):1271-1281
pubmed: 33257899
Nucleic Acids Res. 2018 Sep 6;46(15):e91
pubmed: 29800273
Oncogene. 2020 Jun;39(23):4491-4506
pubmed: 32385348
Nat Commun. 2015 Apr 08;6:6782
pubmed: 25851810
Nucleic Acids Res. 2014;42(17):11011-24
pubmed: 25200076
Mol Cell Biol. 2015 Jan;35(1):88-100
pubmed: 25332240
Oncogene. 2015 Aug 20;34(34):4421-8
pubmed: 25381818
Nat Commun. 2018 Mar 5;9(1):943
pubmed: 29507293
Mol Cell Biol. 2003 Oct;23(19):7030-43
pubmed: 12972619
Mol Cell Biol. 2002 Jul;22(13):4952-64
pubmed: 12052899
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Rev Genet. 2020 May;21(5):292-310
pubmed: 31988385
J Biol Chem. 2011 Nov 25;286(47):40974-86
pubmed: 21937452
J Invest Dermatol. 2008 Mar;128(3):530-41
pubmed: 17882273
Nat Genet. 2019 Jan;51(1):128-137
pubmed: 30478436
Bioinformatics. 2016 Aug 15;32(16):2528-30
pubmed: 27153642
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):11-23
pubmed: 31034924
Cancer Res. 2014 Jul 15;74(14):3983-94
pubmed: 24830720
J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73
pubmed: 15564374
Nat Genet. 2018 Dec;50(12):1744-1751
pubmed: 30374068
Oncogene. 2005 Jan 27;24(5):801-9
pubmed: 15558021
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44
pubmed: 23483055
Nature. 2014 Aug 7;512(7512):96-100
pubmed: 25043061
Cell Cycle. 2007 Nov 1;6(21):2633-9
pubmed: 17957143
Mol Cell. 2017 Sep 21;67(6):1037-1048.e6
pubmed: 28890333
Curr Opin Chem Biol. 2018 Aug;45:195-203
pubmed: 30025258
Nat Rev Cancer. 2003 Nov;3(11):859-68
pubmed: 14668816
PLoS Genet. 2012;8(6):e1002769
pubmed: 22737084
Transcription. 2013 Jan-Feb;4(1):18-23
pubmed: 23131664
Cell Signal. 2009 Jun;21(6):969-77
pubmed: 19249353
BMC Genomics. 2019 Feb 1;20(1):103
pubmed: 30709337
Nat Cell Biol. 2002 May;4(5):E131-6
pubmed: 11988758
Cancer Cell. 2013 Sep 9;24(3):347-64
pubmed: 24029232
Oncotarget. 2017 Mar 15;8(13):20572-20587
pubmed: 28411283
Mol Biol Rep. 2020 Jan;47(1):737-752
pubmed: 31612408
Brief Bioinform. 2020 May 21;21(3):836-850
pubmed: 30895290
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
Nat Commun. 2019 Nov 27;10(1):5412
pubmed: 31776347
EMBO J. 2003 Jul 15;22(14):3686-95
pubmed: 12853483
Oncogene. 2012 Nov 22;31(47):4889-97
pubmed: 22286759
Mol Cancer Res. 2019 Oct;17(10):1999-2014
pubmed: 31300541
Mol Cell Biol. 2007 Jun;27(11):3936-50
pubmed: 17371847
Nat Commun. 2019 Sep 25;10(1):4369
pubmed: 31554806
BMC Genomics. 2019 Jun 20;20(1):511
pubmed: 31221079
Nat Genet. 2018 Aug;50(8):1151-1160
pubmed: 29988121
Epigenomics. 2018 Apr 1;10(4):483-498
pubmed: 29583027
J Cell Sci. 2003 Dec 15;116(Pt 24):4957-63
pubmed: 14625389
Eur J Cancer. 2010 Jun;46(9):1650-60
pubmed: 20226654
Nat Cell Biol. 2002 Aug;4(8):556-64
pubmed: 12134156
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Mol Cell. 2020 Jan 16;77(2):324-337.e8
pubmed: 31704182
Oncogene. 2005 Feb 17;24(8):1434-44
pubmed: 15608675
Nat Rev Genet. 2020 Feb;21(2):71-87
pubmed: 31605096
Cancer Lett. 2017 Jan 28;385:97-107
pubmed: 27816489
J Biol Chem. 2016 Mar 25;291(13):6714-22
pubmed: 26851278
Nat Genet. 2017 Jul;49(7):1073-1081
pubmed: 28581502